Interleukin-1 receptor antagonist inhibits angiogenesis in gastric cancer

[1] England H(2014)Release of interleukin-1α or interleukin-1β depends on mechanism of cell death J Biol Chem 289 15942-15950

[2] Summersgill HR(2013)Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves J Cancer 4 3-11

[3] Edye ME(2013)Opposing functions of classic and novel IL-1 family members in gut health and disease J Front Immunol 4 181-220

[4] Sevko A(2006)Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment J Transl Med 4 48-19

[5] Umansky V(2010)Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models J Biochim Biophys Acta 1803 3-721

[6] Lopetuso LR(2014)Molecular regulation of bone marrow metastasis in prostate and breast cancer J Bone Marrow Res 2014 405920-262

[7] Chowdhry S(2011)Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases J Allergy Clin Immunol 127 701-580

[8] Pizarro TT(2002)Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes J Matrix Biol 21 251-1314

[9] Lewis AM(2004)Vascular endothelial growth factor and angiogenesis J Pharmacol Rev 56 549-290

[10] Varghese S(2015)CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer J Cancer Let 359 335-3149

[1] England H(2014)Release of interleukin-1α or interleukin-1β depends on mechanism of cell death J Biol Chem 289 15942-15950

[2] Summersgill HR(2013)Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves J Cancer 4 3-11

[3] Edye ME(2013)Opposing functions of classic and novel IL-1 family members in gut health and disease J Front Immunol 4 181-220

[4] Sevko A(2006)Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment J Transl Med 4 48-19

[5] Umansky V(2010)Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models J Biochim Biophys Acta 1803 3-721

[6] Lopetuso LR(2014)Molecular regulation of bone marrow metastasis in prostate and breast cancer J Bone Marrow Res 2014 405920-262

[7] Chowdhry S(2011)Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases J Allergy Clin Immunol 127 701-580

[8] Pizarro TT(2002)Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes J Matrix Biol 21 251-1314

[9] Lewis AM(2004)Vascular endothelial growth factor and angiogenesis J Pharmacol Rev 56 549-290

[10] Varghese S(2015)CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer J Cancer Let 359 335-3149